

Radium-223 ALSYMPCA

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Reviewed, but not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Radium-223 ALSYMPCA

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival




Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers

Therapeutic Indication: Treatment of adult patients with mCRPC, symptomatic bone metastases and no known visceral metastases, in progression after ≥ 2 prior lines of systemic therapy for mCRPC (other than LHRH analogues), or ineligible for any available systemic mCRPC treatment

Experimental Arm: Radium-223 + Best standard of care

Control Arm: Best standard of care + placebo



